Advocacy

The Impact of Crohn’s Perianal Fistula on Quality of Life: Results of an International Patient Survey

The Impact of Crohn’s Perianal Fistula on Quality of Life: Results of an International Patient Survey

August 2023

An international patient survey examined the impact of Crohn’s perianal fistula on patients' quality of life. Patients with both Crohn’s disease and perianal fistulae reported significantly greater negative effects on overall quality of life, well-being, relationships, social life, and work life compared to those with only Crohn’s disease. The study highlights the need for targeted therapeutic strategies to address these burdens.

Read time: 1 min

Horizon Europe - FIBROTARGET

EFCCA is involved in an exciting new Horizon Europe project called FIBROTARGET. This project aims to validate novel immunotherapeutic targets against fibrosis in inflammatory bowel disease in order to obtain patients and regulatory approval for implementation of these novel noninvasive imaging modalities as diagnostic and prognostic tools for fibrotic IBD.

Read time: 2 mins

A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence

A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence

November, 2022

The study developed a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Other indicators include, for example, clinical, endoscopic, and biomarker remission, fatigue, and urgency to go to the toilet. 

Read time: 1 min

World IBD Day 2023

IBD HAS NO AGE is an EFCCA campaign started in 2022 in order to raise awareness of how Inflammatory Bowel Disease (IBD) is impacting on the life of people aged 60 years and over. This year, for World IBD Day 2023 (19 May), we will launch a survey on people with IBD aged 60 years and over to investigate more on this topic with questions related to both quality of care and quality of life. 

Read time: 3 mins

Horizon Europe - METHYLOMIC

The METHYLOMIC project will build on multiple previous cohort studies that confirmed epigenetic biomarkers (specifically DNA methylation) as the most stringent predictor of response to biological therapy, zooming in on CD. DNA methylation profiles in peripheral blood as biomarkers of response/deep remission for three approved biologicals in CD have been specifically discovered and validated.

Read time: 2 mins